Effects of chronic antagonism of endocannabinoid-1 receptors on glucose tolerance and insulin action in skeletal muscles of lean and obese zucker rats

CardioRenal Medicine

Volumn 1, Issue 1, 2011, Pages 31-44

  Lindborg, Katherine A ^a   Jacob, Stephan ^b   Henriksen, Erik J ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Cardio metabolic Institute   (Germany)

Author keywords

CB1 receptor; Insulin resistance; Soleus muscle; SR141716; Zucker rat

Indexed keywords

EID: 84863419730     PISSN: 16643828     EISSN: 16645502     Source Type: Journal    
DOI: 10.1159/000322826     Document Type: Article

References (37)

1. Kakafika AI, Mikhailidis DP, Karagiannis A, Athyros VG: The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. J Clin Pharmacol 2007; 7: 642-652.
2. Herling AW, Gossel M, Harschke G, Stengelin S, Kuhlmann J, Müller G, Schmoll D, Kramer W: CB1 receptor antagonist AVE1625 affects primarily metabolic parameters independently of reduced food intake in Wistar rats. Am J Physiol Endocrinol Metab 2007; 93:E826-E832.
3. Matias I, Di Marzo V: Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007; 18: 27-37. 4 Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschöp MH: Peripheral, but not central, CM1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008; 57: 2977-2991.
4. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschöp MH: Peripheral, but not central, CM1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008; 57
5. Di Marzo V, Goparaju SK, Wang L, Liu J, Bátkal S, Járai Z, Fezza F, Miura GI, Palmiter RD, Suguira T, Kunos G: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
6. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA: Preferential effects of the cannabinoid CB1 receptor antagonist, SR141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology (Berl) 2003; 167: 103-111.
7. Scheen AJ, Paquot N: Inhibitors of cannabinoid receptors and glucose metabolism. Curr Opin Clin Nutr Metab Care 2008; 11: 505-511.
8. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, Tomassoni F, ervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
9. Liu YL, Connoley IP, Wilson CA, Stock MJ: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep ob /Lep ob mice. Int J Obes 2005; 29: 183-187.
10. Berm údez-Siva FJ, Serran A, Diaz-Molina FJ, Sánchez Vera I, Juan Pico P, Nadal A, Fuentes E, Rodríguez de Fonseca F: Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006; 531: 282-284.
11. Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, Seeley RJ, Obici S: Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity 2009; 17: 1641-1645.
12. Duvivier VF, Delafoy-Plasse L, Delion V, Lechevalier P, Le Bail JC, Guillot E, Pruniaux MP, Galzin AM: Beneficial effect of a chronic treatment with rimonabant on pancreatic function and ß-cell morphology in Zucker fatty rats. Eur J Pharmacol 2009; 616: 314-320.
13. Flamment M, Gueguen N, Wetterwald C, Simard G, Malthièry Y, Ducluzeau PH: Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet. Am J Physiol Endocrinol Metab 2009; 297:E1162-E1170.
14. Després JP, Ross R, Boka G, Alméras N, Lemieux I, ADAGIO-Lipids Investigators: Effect of rimonabant on the hightriglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009; 29: 416-423.
15. Gary-Bobo M, Elachouri G, Gallas JF, Janiak P, Marini P, Ravinet-Trillou C, Chabbert M, Cruccioli N, Pfersdorff C, Roque C, Arnone M, Croci T, Soubrié P, Oury-Donat F, Maffrand JP, Scatton B, Lacheretz F, Le Fur G, Herbert JM, Bensaid M: Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46: 122-129.
16. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrié P: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284:R345-R353.
17. Henriksen EJ, Halseth AE: Early alterations in soleus GLUT-4, glucose transport, and glycogen in voluntary running rats. J Appl Physiol 1994; 76: 1862-1867.
18. Hansen PA, Gulve ES, Holloszy JO: Suitability of 2-deoxyglucose for in vitro measurement of glucose transport activity in skeletal muscle. J Appl Physiol 1994; 76: 979-985.
19. Cortez MY, Torgan CE, Brozinick JT, Ivy JL: Insulin resistance of obese Zucker rats exercise trained at two different intensities. Am J Physiol Endocrinol Metab 1991; 261:E613-E619.
20. Lindborg KA, Teachey MK, Jacob S, Henriksen EJ: Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle. Diabetes Obes Metab 2010; 12: 722-730.
21. Cavuoto P, McAinch AJ, Hatzinikolas G, Cameron-Smith D, Wittert GA: Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 2007; 267: 63-69.
22. Esposito I, Proto MC, Gazzerro P, Laezza C, Miele C, Alberobello AT, D'Esposito V, Beguinot F, Formisano P, Bifulco M: The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008; 74: 1678-1686.
23. Eckardt K, Sell H, Taube A, Koenen M, Platzbecker B, Cramer A, Horrighs A, Lehtonen M, Tennagels N, Eckel J: Cannabinoid type 1 receptors in human skeletal muscle cells participate in the negative crosstalk between fat and muscle. Diabetologia 2009; 52: 664-674.
24. Watanabe T, Kubota N, Ohsugi M, Kubota T, Takamoto I, Iwabu M, Awazawa M, Katsuyama H, Hasegawa C, Tokuyama K, Moroi M, Sugi K, Yamauchi T, Noda T, Nagai R, Terauchi Y, Tobe K, Ueki K, Kadowaki T: Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways. J Biol Chem 2009; 284: 1803-1812.
25. Lipina C, Stretton C, Hastings S, Hundal JS, Mackie K, Irving AJ, Hundal HS: Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes 2010; 59: 375-385.
26. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI: Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103: 253-259.
27. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI: Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 1999; 48: 1270-1274.
28. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem 2002; 277: 50230-50236.
29. Taube A, Eckardt K, Eckel J: Role of lipid-derived mediators in skeletal muscle in insulin resistance. Am J Physiol Endocrinol Metab 2009; 297:E1004-E1012.
30. Cartee GD, Dean DJ: Glucose transport with brief dietary restriction: heterogenous responses in muscles. Am J Physiol Endocrinol Metab 1994; 266:E946-E952.
31. McCurdy CE, Davidson RT, Cartee GD: Calorie restriction increases the ratio of phosphatidylinositol 3-kinase catalytic to regulatory subunits in rat skeletal muscle. Am J Physiol Endocrinol Metab 2005; 288:E996-E1001.
32. McCurdy CE, Davidson RT, Cartee GD: Brief calorie restriction increases Akt2 phosphorylation in insulin-stimulated rat skeletal muscle. Am J Physiol Endocrinol Metab 2003; 285:E693-E700.
33. Xie S, Furjanic MA, Ferrara JJ, McAndrew NR, Ardino EL, Ngondara A, Bernstein Y, Thomas KJ, Kim E, Walker JM, Nagar S, Ward SJ, Raffa RB: The endocannabinoid system and rimonabant: a new drug with a novel mechanism of action involving cannabinoid CB1 receptor antagonism - or inverse agonism - as potential obesity treatment and other therapeutic use. J Clin Pharm Ther 2007; 32: 209-231.
34. de Kloet AD, Woods SC: Minireview: endocannabinoids and their receptors as targets for obesity therapy. Endocrinology 2009; 150: 2531-2536.
35. D'Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira SR: The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008; 57: 1262-1268.
36. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, Jordan J: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2008; 54: 2838-2843.
37. Blüher M, Engeli S, Klöting N, Berndt J, Fasshauer M, Bátkai S, Pacher P, Schön MR, Jordan J, Stumvoll M: Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.